Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -30.34
- Piotroski Score 2.00
- Grade Buy
- Symbol (ONCT)
- Company Oncternal Therapeutics, Inc.
- Price $1.12
- Changes Percentage (-3.45%)
- Change -$0.04
- Day Low $1.10
- Day High $1.16
- Year High $13.20
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/06/2025
- Fiscal Year End N/A
- Average Stock Price Target $28.00
- High Stock Price Target $28.00
- Low Stock Price Target $28.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$12.33
- Trailing P/E Ratio -0.67
- Forward P/E Ratio -0.67
- P/E Growth -0.67
- Net Income $-39,479,000
Income Statement
Quarterly
Annual
Latest News of ONCT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
What does $2.25M get you in Moncton, N.B.? This viral video offers a glimpse - New Brunswick | Globalnews.ca
A social media reel showcasing a luxurious mansion in New Brunswick has gone viral, attracting over 300,000 views. The 6,000 sq ft estate with unique features like an indoor pool and wine cellar is li...
By Global News | 2 months ago
